Abstract
Typhoid in Africa and vaccine deployment
Highlights
Typhoid, one of the classic infectious diseases afflicting humanity, is still a relatively common illness in many lower-income and middle-income countries (LMIC).[1]
Multidrug resistance has been increasingly reported as a characteristic of S Typhi isolated in the past decade and from different parts of the globe.[4]
Multidrug resistant S Typhi respond more slowly to antibiotic treatment,[7] and such strains might be stimulating an increased use of antibiotics in the community, where antibiotics are freely available without prescription
Summary
One of the classic infectious diseases afflicting humanity, is still a relatively common illness in many lower-income and middle-income countries (LMIC).[1]. These are not always present in LMIC settings and the incidence of typhoid in many regions, Africa, remains relatively undefined. A new generation of typhoid vaccines, based on conjugate technology and the Vi capsular antigen of S Typhi, are being developed and have been licenced in some countries.[8]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call